thiophenes has been researched along with Myocardial Ischemia in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (10.26) | 18.2507 |
| 2000's | 10 (25.64) | 29.6817 |
| 2010's | 24 (61.54) | 24.3611 |
| 2020's | 1 (2.56) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, Q; Lei, S; Qiu, Z; Tian, L; Xia, ZY; Zhao, B; Zhao, X | 1 |
| Alibhai, FJ; Bridle, BW; Burris, TP; Khatua, TN; Martino, TA; Rasouli, M; Reitz, CJ | 1 |
| Fu, F; Huang, Y; Lu, Y; Lv, H; Sha, C; Wang, T; Yu, F; Zhai, R; Zhang, L | 1 |
| Alexopoulos, D; Xanthopoulou, I | 1 |
| Gurbel, PA; Tantry, US | 2 |
| Kastrati, A; Martischnig, A; Mayer, K; Mehilli, J; Sarafoff, N; Sibbing, D; Wealer, J | 1 |
| Alexopoulos, D; Davlouros, P; Hahalis, G; Perperis, A; Siapika, A; Stavrou, K; Tsoni, E; Xanthopoulou, I | 1 |
| Gómez de Diego, JJ; López Sendón, JL; Montoro López, N; Peña Conde, L | 1 |
| Fosbøl, EL; Gislason, GH; Hansen, ML; Køber, L; Lamberts, M; Mikkelsen, AP; Olesen, JB; Sørensen, R; Torp-Pedersen, C; Weeke, P | 1 |
| Braunwald, E; Cohen, DJ; Cutlip, DE; Dauerman, HL; Driscoll-Shempp, P; Garratt, KN; Hermiller, J; Holmes, DR; Kandzari, DE; Kereiakes, DJ; Krucoff, MW; Lee, DP; Massaro, JM; Mauri, L; Normand, SL; Pow, TK; Rinaldi, MJ; Simon, DI; Steg, PG; Ver Lee, P; Wiviott, SD; Yeh, RW | 1 |
| Belle, L; Boueri, Z; Carrié, D; Cayla, G; Collet, JP; Cuisset, T; Delarche, N; El Mahmoud, R; Elhadad, S; Etienne, CS; Henry, P; Leclercq, F; Montalescot, G; Motreff, P; Pouillot, C; Rangé, G; Silvain, J; Van Belle, E; Varenne, O; Vicaut, E | 1 |
| Holper, EM; Luna, M | 1 |
| Bode, C; Cohen, M; Fox, K; Gibson, CM; Halperin, J; Husted, S; Lip, GY; Mehran, R; Peterson, E; van Eickels, M; Verheugt, F; Wildgoose, P | 1 |
| Liakishev, AA | 1 |
| Abramson, J; Allbaugh, RA; Alter, H; Amano, C; Amicarella, F; Ara, N; Armengou, L; Asano, N; Bai, SJ; Ben-Shlomo, G; Benoit, E; Bhatnagar, A; Bolli, R; Boulanger, F; Brohawn, P; Brouchkov, A; Buckner, JD; Bukh, J; Buysschaert, C; Carlson, M; Cesarini, C; Cheng, L; Chipinda, I; Cogle, CR; Cooke, JP; Costa, DB; Damotte, D; Das, S; Däster, S; De Chatterjee, A; De Leon, J; Delko, T; Devi, P; Dieu-Nosjean, MC; Droeser, RA; Duarte, T; Ebert, RF; Ecker, AH; Ellis, SG; Eppenberger-Castori, S; Farhoudi, A; Folch, E; Foster, DW; Frasson, D; Fujishima, F; Gangadharan, SP; Gao, W; Germain, C; Glanemann, M; Governa, V; Grant, MB; Hammond, SA; Han, CX; Haspel, RL; He, X; Heberer, M; Henry, TD; Hettick, J; Higgs, BW; Hirt, C; Huang, Y; Huberman, MS; Iezzi, G; Iijima, K; Imatani, A; Ishikawa, N; Izumi, H; Jeon, CO; Jessell, L; Joblin, C; Johnstone, BH; Jose-Cunilleras, E; Joseph, LJ; Jung, WY; Kanazawa, I; Kang, N; Kawaguchi, K; Kawai, K; Kent, MS; Kettelhack, C; Khurshid, SS; Kinney, KA; Kitajima, S; Knockaert, S; Koike, T; Kubo, M; Kuroda, E; Lai, D; Laschke, MW; Lassiter, T; Le, X; Lee, HJ; Lehmann, K; Li, D; Li, F; Li, J; Li, XX; Liu, J; Liu, Y; Liu, YY; Liu, Z; Ma, J; Maejima, R; Majid, A; Makielski, KM; Man, S; Mao, M; Margesin, R; Martincigh, BS; Maruyama, R; Mele, V; Mendez, TL; Menger, MD; Meuleman, P; Miyake, H; Morakinyo, MK; Morimoto, Y; Moussavian, MR; Moyé, L; Myojo, T; Nebiker, CA; Nejad, SA; Nestor, B; Noguchi, T; Oertli, D; Onaka, T; Orozco, A; Oyabu, T; Padovan, E; Pepine, CJ; Perin, EC; Pilleri, P; Prentoe, J; Qiu, P; Rangachari, D; Resende, M; Ríos, J; Robles-Martinez, L; Safarzadeh, MA; Sahraei, E; Salehi, MM; Sasaki, T; Sayre, SL; Schlachtenberger, G; Schutt, RC; Sconocchia, G; Sebastian, Y; Shimada, M; Shimosegawa, T; Siegel, JA; Siegel, PD; Simari, RD; Simoyi, RH; Song, YH; Soysal, SD; Spagnoli, GC; Strongin, R; Sugimoto, T; Tanaka, KI; Tang, XD; Tao, Y; Taylor, DA; Terracciano, L; Thiessen, CE; Tofflemire, KL; Tomonaga, T; Tornillo, L; Traverse, JH; Uno, K; Valge-Archer, V; Validire, P; VanderLaan, PA; Velázquez Moctezuma, R; Verhoye, L; Viu, J; von Heesen, M; von Holzen, U; Wagner, M; Wang, FY; Wang, R; Weixler, B; Whitley, RD; Willerson, JT; Windsor, LC; Wise, E; Wu, FZ; Wu, ZY; Yamamoto, K; Yano, S; Yao, Y; Yatera, K; Yin, Q; Yoshiura, Y; Zhang, DC; Zhang, L; Zhao, DX; Zhou, Y; Zhu, W; Zhu, X; Zierold, C; Zvolensky, MJ | 1 |
| Ramaraj, R | 1 |
| Angiolillo, DJ; Antman, EM; Braunwald, E; Corbalan, R; Dalby, AJ; Goodman, SG; McCabe, CH; Meisel, S; Murphy, SA; Purdy, DA; Verheugt, FW; Wiviott, SD | 1 |
| Solomon, S; Vacek, JL | 1 |
| Capodanno, D; Tamburino, C | 1 |
| Davidson, SM; Gonçalves, LM; Mocanu, MM; Paiva, MA; Providência, LA; Rutter-Locher, Z; Yellon, DM | 1 |
| James, S; Varenhorst, C | 1 |
| Bessereau, J; Bonello, L; Camoin-Jau, L; Collet, F; Dignat-George, F; Jouve, B; Laine, M; Lemesle, G; Maillard, L; Mancini, J; Michelet, P; Paganelli, F; Pansieri, M; Rossi, P; Wittenberg, O | 1 |
| Benedetti, G; Biondi-Zoccai, G; Calcagno, S; Canali, E; Di Roma, A; Fedele, F; Guadagni, F; Lucisano, L; Mancone, M; Palmirotta, R; Pennacchi, M; Sardella, G; Stio, RE | 1 |
| Armstrong, PW; Brown, E; Chan, MY; Cornel, JH; Erlinge, D; Fox, KA; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Neely, B; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD; Zhou, C | 1 |
| Chevalier, B; Diletti, R; Dorange, C; Farooq, V; Garcia-Garcia, HM; Miquel-Hebert, K; Onuma, Y; Rapoza, R; Serruys, PW; Sudhir, K; Veldhof, S | 1 |
| Angiolillo, DJ; Seecheran, NA; Tello-Montoliu, A | 1 |
| Baeriswyl, G; Cook, S; Goy, JJ; Lehmann, S; Lehner, C; Oberhänsli, M; Puricel, S; Stauffer, JC; Togni, M | 1 |
| Ali, F; Bone, RF; Crysler, CS; Cummings, MD; DesJarlais, RL; Illig, CR; Jonathan Rudolph, M; Khalil, E; Kilpatrick, JM; Klein, S; Morris, PE; Soll, RM; Spurlino, JC; Subasinghe, NL; Sudhakara Babu, Y | 1 |
| Ali, F; Ballentine, SK; Bone, RF; Crysler, CS; Cummings, MD; DesJarlais, RL; Huang, H; Hufnagel, HR; Khalil, E; Marugán, JJ; Molloy, CJ; Ninan, N; Subasinghe, NL; Tomczuk, BE; Travins, JM | 1 |
| Lowry, DR; Malinin, AI; Meilman, H; Midei, MG; Serebruany, VL | 1 |
| Antman, EM; Braunwald, E; Chandna, H; Hasin, Y; Macias, W; McCabe, CH; Murphy, SA; Voitk, J; Widimsky, P; Wiviott, SD | 1 |
| Auchampach, JA; Bruns, RF; Gross, GJ; Linden, J; Mizumura, T | 1 |
| Richardt, G; Schreieck, J | 1 |
| Folkes, A; Nutting, C | 1 |
| Auguet, M; Auvin, S; Bigg, D; Chabrier, PE; Cornet, S; Demerlé-Pallardy, C; Gillard-Roubert, V; Guilmard-Favre, C; Marin, JG; Moncada, S; Pignol, B; Roussillot-Charnet, C; Schulz, J; Spinnewyn, B; Viossat, I | 1 |
| Goto, T; Maeda, K; Ohara, F; Ozaki, T; Seki, J; Yamamoto, N | 1 |
| Goto, T; Maeda, K; Ohara, F; Ohkubo, K; Seki, J | 1 |
3 review(s) available for thiophenes and Myocardial Ischemia
| Article | Year |
|---|---|
Use of novel antiplatelet agents in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Animals; Coronary Artery Disease; Hemorrhage; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes | 2015 |
Which antiplatelet agent for whom? Which patient populations benefit most from novel antiplatelet agents (ticagrelor, prasugrel)?
Topics: Acute Coronary Syndrome; Adenosine; Hemorrhage; Humans; Myocardial Ischemia; Patient Selection; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor | 2012 |
Aspirin and clopidogrel resistance: consideration and management.
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Restenosis; Drug Resistance; Humans; Membrane Proteins; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12; Thiophenes; Ticagrelor; Ticlopidine | 2006 |
11 trial(s) available for thiophenes and Myocardial Ischemia
| Article | Year |
|---|---|
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrhage; Humans; Incidence; Male; Middle Aged; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombosis; Ticlopidine; Time Factors | 2014 |
Platelet function monitoring in elderly patients on prasugrel after stenting for an acute coronary syndrome: design of the randomized antarctic study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Drug Monitoring; Hemorrhage; Humans; Myocardial Ischemia; Percutaneous Coronary Intervention; Piperazines; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Stents; Thiophenes; Treatment Outcome | 2014 |
An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention
Topics: Administration, Oral; Aged; Atrial Fibrillation; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrocardiography; Factor Xa Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Morpholines; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Retrospective Studies; Rivaroxaban; Thiophenes; Ticlopidine; Treatment Outcome; Vitamin K | 2015 |
[Twelve or thirty months of dual antiplatelet Therapy after drug-eluting stents. Results of the DAPT trial].
Topics: Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myocardial Ischemia; Myocardial Revascularization; Piperazines; Platelet Aggregation Inhibitors; Postoperative Care; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial I
Topics: Administration, Oral; Aged; Clopidogrel; Coronary Thrombosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Thiophenes; Thrombolytic Therapy; Ticlopidine; Treatment Outcome | 2008 |
Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Confidence Intervals; Double-Blind Method; Drug Therapy, Combination; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pyridines; Thiophenes; Ticlopidine | 2010 |
Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
Topics: Aged; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Cytochrome P-450 CYP2C19; Drug Substitution; Female; Genotype; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Coronary Intervention; Phenotype; Piperazines; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Rome; Thiophenes; Ticlopidine; Treatment Outcome | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Stroke; Thiophenes; Ticlopidine; Treatment Outcome | 2012 |
ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatm
Topics: Absorbable Implants; Adult; Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary Thrombosis; Drug-Eluting Stents; Europe; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Myocardial Ischemia; New Zealand; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Research Design; Sample Size; Single-Blind Method; Sirolimus; Spectroscopy, Near-Infrared; Thiophenes; Tissue Scaffolds; Tomography, X-Ray Computed; Ultrasonography, Interventional | 2012 |
A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: the CLO-CLO trial.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Clopidogrel; Cross-Over Studies; Drugs, Generic; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Patient Selection; Percutaneous Coronary Intervention; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Single-Blind Method; Stents; Therapeutic Equivalency; Thiophenes; Thrombosis; Ticlopidine; Treatment Outcome | 2012 |
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Combination; Hemorrhage; Humans; Kaplan-Meier Estimate; Myocardial Infarction; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Proportional Hazards Models; Purinergic P2 Receptor Antagonists; Stents; Thiophenes; Ticlopidine | 2008 |
25 other study(ies) available for thiophenes and Myocardial Ischemia
| Article | Year |
|---|---|
Rev-erbs agonist SR9009 alleviates ischemia-reperfusion injury by heightening endogenous cardioprotection at onset of type-2 diabetes in rats: Down-regulating ferritinophagy/ferroptosis signaling.
Topics: Animals; Diabetes Mellitus, Type 2; Ferroptosis; Glycolipids; Myocardial Ischemia; Myocardial Reperfusion Injury; Pyrrolidines; Rats; Thiophenes | 2022 |
SR9009 administered for one day after myocardial ischemia-reperfusion prevents heart failure in mice by targeting the cardiac inflammasome.
Topics: Animals; Biomarkers; Biopsy; Heart Failure; Immunohistochemistry; Inflammasomes; Mice; Myocardial Ischemia; Myocardial Reperfusion; NLR Family, Pyrin Domain-Containing 3 Protein; Nuclear Receptor Subfamily 1, Group D, Member 1; Pyrrolidines; Thiophenes | 2019 |
Effects of rotigotine and rotigotine extended-release microsphere therapy on myocardial ischemic injury in mice.
Topics: Animals; Cardiotonic Agents; Chlorpromazine; Creatine Kinase, MB Form; Dopamine Agonists; Isoproterenol; Male; Mice; Microspheres; Models, Animal; Myocardial Ischemia; Myocytes, Cardiac; Parkinson Disease; Tetrahydronaphthalenes; Thiophenes; Troponin I | 2019 |
Letter by Alexopoulos et al regarding article, "pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel dose versus prasugrel: the RESET GENE Trial".
Topics: Aryl Hydrocarbon Hydroxylases; Blood Platelets; Coronary Artery Disease; Drug Substitution; Female; Humans; Male; Myocardial Ischemia; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine | 2013 |
Triple antithrombotic therapy with prasugrel in the stented patient: concern for more bleeding.
Topics: Anticoagulants; Aspirin; Drug-Eluting Stents; Female; Humans; Male; Myocardial Ischemia; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes | 2013 |
Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Drug-Eluting Stents; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Patient Selection; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticlopidine; Vitamin K | 2013 |
Factors affecting residual platelet aggregation in prasugrel treated patients.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Cohort Studies; Drug Resistance; Female; Heart Diseases; Hemorrhage; Humans; Maintenance Chemotherapy; Male; Middle Aged; Models, Biological; Myocardial Ischemia; Percutaneous Coronary Intervention; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Postoperative Complications; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Smoking; Thiophenes | 2013 |
[Systemic aneurysms in Behçet's disease].
Topics: Adult; Aneurysm, Ruptured; Behcet Syndrome; Cerebral Hemorrhage; Combined Modality Therapy; Coronary Aneurysm; Coronary Restenosis; Drug-Eluting Stents; Humans; Intracranial Aneurysm; Male; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Rupture, Spontaneous; Stents; Thiophenes | 2013 |
Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Atrial Fibrillation; Benzimidazoles; beta-Alanine; Comorbidity; Dabigatran; Denmark; Female; Heart Failure; Humans; Male; Middle Aged; Morpholines; Myocardial Infarction; Myocardial Ischemia; Practice Patterns, Physicians'; Pyrazoles; Pyridones; Registries; Renal Insufficiency, Chronic; Rivaroxaban; Sex Factors; Stroke; Thiophenes; Warfarin | 2015 |
Topics: Acid-Base Imbalance; Acidosis, Renal Tubular; Aged; Air Pollution, Indoor; Amino Acid Substitution; Animals; Animals, Newborn; Anti-Bacterial Agents; Antibodies, Neutralizing; Apoptosis; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Bone Marrow Transplantation; Carbonic Anhydrase Inhibitors; Castleman Disease; Cat Diseases; Cats; Cell Proliferation; Cell- and Tissue-Based Therapy; Chemical and Drug Induced Liver Injury; Chemotaxis, Leukocyte; Clinical Trials as Topic; Coated Materials, Biocompatible; Diagnosis, Differential; Disease Models, Animal; Environmental Monitoring; Female; Gas Chromatography-Mass Spectrometry; Genotype; Granuloma, Foreign-Body; Heart Failure; Hepacivirus; Hepatitis C; Horse Diseases; Horses; Housing; Humans; Hypercalcemia; Hypokalemia; Immunophenotyping; In Vitro Techniques; Liver; Liver Function Tests; Lymphocytes; Macrophages; Male; Medicine, Chinese Traditional; Metabolomics; Mice; Mice, Inbred C57BL; Middle Aged; Models, Animal; Mutation; Myocardial Ischemia; Neovascularization, Physiologic; Neutrophil Infiltration; Ocular Hypertension; Ophthalmic Solutions; Parathyroid Hormone; Particulate Matter; Polyethylene Terephthalates; Prednisolone; Prospective Studies; Prosthesis Design; Prosthesis-Related Infections; Rats; Rats, Wistar; Reactive Oxygen Species; Rifampin; Saponins; Sepsis; Skin; Stem Cells; Stroke Volume; Sulfonamides; Texas; Thiophenes; Time Factors; Ventricular Dysfunction, Left; Ventricular Function, Left; Viral Hepatitis Vaccines; Viral Nonstructural Proteins; Viral Proteins; Vitamin D; Wound Healing | 2015 |
Intensive antiplatelet therapy for reduction of ischaemic events.
Topics: Clopidogrel; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine; Time Factors | 2008 |
[New thrombocyte inhibitor. Fewer ischemic complications in acute coronary syndrome].
Topics: Acute Coronary Syndrome; Clopidogrel; Double-Blind Method; Humans; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Ticlopidine | 2009 |
Cyphering the statistical and clinical significance of prasugrel in the TRITON-TIMI 38 trial.
Topics: Acute Coronary Syndrome; Clinical Trials, Phase III as Topic; Data Interpretation, Statistical; Humans; Myocardial Ischemia; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Risk Factors; Thiophenes | 2011 |
Enhancing AMPK activation during ischemia protects the diabetic heart against reperfusion injury.
Topics: AMP-Activated Protein Kinases; Animals; Biphenyl Compounds; Cells, Cultured; Diabetes Mellitus; Disease Models, Animal; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Male; Microtubule-Associated Proteins; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocytes, Cardiac; Phosphorylation; Pyrones; Rats; Rats, Inbred Strains; Rats, Wistar; Thiophenes | 2011 |
Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel.
Topics: Acute Coronary Syndrome; Blood Platelets; Cell Adhesion Molecules; Coronary Thrombosis; Female; Follow-Up Studies; France; Hemorrhage; Humans; Kaplan-Meier Estimate; Linear Models; Male; Microfilament Proteins; Middle Aged; Multivariate Analysis; Myocardial Ischemia; Odds Ratio; Percutaneous Coronary Intervention; Phosphoproteins; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Assessment; Risk Factors; Thiophenes; Time Factors; Treatment Outcome | 2012 |
Successful pregnancy and delivery on prasugrel treatment: considerations for the use of dual antiplatelet therapy during pregnancy in clinical practice.
Topics: Adult; Female; Humans; Live Birth; Myocardial Ischemia; Piperazines; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Pregnancy; Pregnancy Complications, Cardiovascular; Purinergic P2Y Receptor Antagonists; Thiophenes | 2013 |
A novel series of potent and selective small molecule inhibitors of the complement component C1s.
Topics: Binding Sites; Complement C1; Complement Inactivator Proteins; Complement Pathway, Classical; Humans; Myocardial Ischemia; Pyrazoles; Serine Endopeptidases; Serine Proteinase Inhibitors; Structure-Activity Relationship; Thiazoles; Thiophenes | 2004 |
A novel series of arylsulfonylthiophene-2-carboxamidine inhibitors of the complement component C1s.
Topics: Amidines; Angioedema; Arylsulfonates; Complement C1s; Fibrinolysin; Graft Rejection; Humans; Myocardial Ischemia; Serine Proteinase Inhibitors; Structure-Activity Relationship; Tetradecanoylphorbol Acetate; Thiophenes; Thrombin; Urokinase-Type Plasminogen Activator | 2006 |
Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial.
Topics: Angina Pectoris; Aspirin; Chronic Disease; Coronary Stenosis; Drug Therapy, Combination; Humans; Male; Middle Aged; Myocardial Ischemia; Piperazines; Platelet Activation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Randomized Controlled Trials as Topic; Thiophenes; Treatment Refusal | 2006 |
PD 81,723, an allosteric enhancer of the A1 adenosine receptor, lowers the threshold for ischemic preconditioning in dogs.
Topics: Allosteric Regulation; Animals; Binding, Competitive; Differential Threshold; Dogs; Female; Glyburide; Hemodynamics; Male; Myocardial Ischemia; Myocardial Reperfusion; Radioligand Assay; Receptors, Purinergic P1; Recombinant Proteins; Thiophenes | 1996 |
Endogenous adenosine reduces the occurrence of ischemia-induced ventricular fibrillation in rat heart.
Topics: Adenine; Adenosine; Aminoimidazole Carboxamide; Animals; Caffeine; Creatine Kinase; Electrocardiography; Enzyme Inhibitors; Hypoxanthine; Inosine; Male; Myocardial Ischemia; Myocardium; Perfusion; Rats; Rats, Wistar; Reperfusion Injury; Ribonucleosides; Theophylline; Thioinosine; Thiophenes; Time Factors; Ventricular Fibrillation; Xanthines | 1999 |
The use of raltitrexed (tomudex) in a patient with 5-fluorouracil induced myocardial ischaemia.
Topics: Antimetabolites, Antineoplastic; Colorectal Neoplasms; Enzyme Inhibitors; Female; Fluorouracil; Humans; Middle Aged; Myocardial Ischemia; Quinazolines; Thiophenes; Thymidylate Synthase | 1999 |
BN 80933, a dual inhibitor of neuronal nitric oxide synthase and lipid peroxidation: a promising neuroprotective strategy.
Topics: Animals; Aorta; Brain Injuries; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gerbillinae; Inhibitory Concentration 50; Kinetics; Lipid Peroxidation; Male; Mice; Myocardial Ischemia; Neurons; Neuroprotective Agents; Nitric Oxide Synthase; Organ Culture Techniques; Pyrazines; Rats; Rats, Sprague-Dawley; Thiophenes; Time Factors | 1999 |
Protective effect of FR183998, a Na+/H+ exchange inhibitor, against postischemic injury after normothermic and prolonged hypothermic ischemia in isolated perfused rat hearts.
Topics: Animals; Blood Flow Velocity; Cardiotonic Agents; Cold Temperature; Creatine Kinase; Guanidines; Heart Arrest, Induced; In Vitro Techniques; Male; Myocardial Ischemia; Myocardial Reperfusion Injury; Rats; Rats, Sprague-Dawley; Rats, Wistar; Sodium-Hydrogen Exchangers; Thiophenes; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Pressure | 2001 |
FR183998, a Na+/H+ exchange inhibitor, suppresses both IL-8 content and myocardial infarct size in a cardiac ischaemia-reperfusion model in rats.
Topics: Animals; Depression, Chemical; Disease Models, Animal; Guanidines; Interleukin-8; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Peroxidase; Rats; Rats, Sprague-Dawley; Sodium-Hydrogen Exchangers; Thiophenes | 2002 |